Ease Labs begins negotiations in Europe to export medical cannabis
The company is evaluating exporting active pharmaceutical ingredients and finished products to Europe as it seeks to expand its international presence beyond the Brazilian market.
The search for international partners is among Ease Labs' expansion fronts in the medical cannabis market. The company is in talks with potential partners in Europe and is assessing opportunities to export active pharmaceutical ingredients and finished products, according to information provided by the firm.
The strategy involves two of the group's operations: Semeya, focused on the production and marketing of cannabis-derived pharmaceutical ingredients, and Ease Labs Pharma, responsible for operations with finished products. Any entry into European markets will depend on commercial conditions and the regulatory requirements of each country.
The company did not detail the countries involved in the talks, the products that could be exported, or the stage of the negotiations. Nor did it disclose timelines for the start of any commercial operations.
Exporting depends on agreements and regulatory requirements
The possibility of exporting medical cannabis involves more than just finding buyers. Active pharmaceutical ingredients and finished products are subject to specific manufacturing, quality, documentation, import, and commercialization requirements in destination markets.
For the company, the international strategy represents an opportunity to expand its presence beyond sales in Brazil. However, bringing this move to fruition depends on formalizing commercial agreements and complying with the applicable rules in each jurisdiction.
The distinction between raw materials and finished products is also relevant when assessing the scope of the initiative. Exporting raw materials intended for the pharmaceutical industry involves different commercial and regulatory conditions than those required for products that will be made directly available in the destination market.
Until the countries involved, the products under negotiation, and the planned terms of the agreements are disclosed, it is not possible to gauge the commercial potential of the initiative.
Brazilian market serves as the foundation for the strategy
The international push comes alongside the expansion of the Brazilian medical cannabis market. Data from IQVIA indicates that sales of cannabidiol products, Cannabis sativa extracts, and THC combinations grew by 12.9% in revenue in the 12 months ending in July 2026. In units, the increase was 30%, rising from 689,000 to 896,000 bottles.
In Ease Labs' portfolio, two products recorded combined revenue growth of 40.5% during the analyzed period. Ease Labs Cannabidiol 100 mg/mL, in a 30 mL presentation, grew 35.7%, while Ease Labs Cannabis sativa Extract 36.76 mg/mL, also in a 30 mL bottle, rose 49.1%.
Data from Close-Up also shows that the two products totaled 561,165 prescriptions between July 2025 and June 2026, an increase of 34.3% compared to the previous 12 months.
These indicators help contextualize the company's performance in the domestic market, but they do not alone allow conclusions regarding its ability to compete abroad. Doing so would require data on international contracts, capacity allocated for export, target markets, and commercial access requirements.
Third-party manufacturing expands the business model
In addition to sales under its own brand, Ease Labs is engaged in the development and manufacturing of products for other pharmaceutical companies. Semeya also supplies ingredients to external companies, expanding the group's operations beyond Brazilian retail.
The company maintains operations related to the supply chain in Colombia, including cultivation and raw material supply, alongside formulation and pharmaceutical manufacturing activities. This structure is part of its international strategy, but does not, on its own, prove that the company has already begun exporting to Europe.
The next relevant milestone will be the conversion of negotiations into contracts, identifying target markets, the products involved, and the requirements needed to make operations viable.
Sources: IQVIA, for market data and retail sales; Close-Up, for prescription data; information provided by Ease Labs.